Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research-Reference-Cited by-同舟云学术

Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research

Published:2018-07 Issue:7 Volume:5 Page:e400-e404
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Dorward Jienchi,Lessells Richard,Drain Paul K,Naidoo Kogieleum,de Oliveira Tulio,Pillay Yogan,Abdool Karim Salim S,Garrett Nigel

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference46 articles.

1. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study;Phillips;Lancet HIV,2018

2. Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection;Walmsley;N Engl J Med,2013

3. Thorne C, Favarato G, Peters H, et al. Pregnancy and neonatal outcomes following prenatal exposure to dolutegravir. 9th IAS Conference on HIV Science; Paris, France; July 23–26, 2017. Abstract 4549.

4. Vannappagari V, Albano J, Ragone L, et al. Dolutegravir use during pregnancy and birth outcomes: data from the Antiretroviral Pregnancy Registry (APR). 9th IAS Conference on HIV Science. Paris, France; July 23–26, 2017. Abstract 68.

5. Zash R, Jacobson DL, Diseko M, et al. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. Lancet Glob Health; in press.

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study;The Lancet Global Health;2024-02

2. HIV drug resistance to integrase inhibitors in low- and middle-income countries;Nature Medicine;2024-01-23

3. Long-acting dolutegravir formulations prevent neurodevelopmental impairments in a mouse model;Frontiers in Pharmacology;2023-12-12

4. Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial;Trials;2023-12-01

5. Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV/AIDS;Medicine;2023-11-10